Spots Global Cancer Trial Database for First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
Official Title: A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-MAB in Participants With Advanced Cancer
Study ID: NCT05159440
Interventions
Study Description
Brief Summary: This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Providence St. Jude Medical Center, Fullerton, California, United States
UCLA - JCCC Clinical Research Unit, Los Angeles, California, United States
Torrance Memorial Medical, Torrance, California, United States
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
Seoul National University Hospital, Seoul, , Korea, Republic of
Severance Hospital, Yonsei University Health System, Seoul, , Korea, Republic of
Seoul National University Bundang Hospital, Seoul, , Korea, Republic of
Contact Details
Name: Stephen Letrent, PharmD, PhD
Affiliation: TORL Biotherapeutics, LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
